Back to search results

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Castrate Resistant Prostate Cancer · NUT Carcinoma · Chronic Myelomonocytic Leukemia · Myelofibrosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic Arizona, Phoenix, Arizona, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015
    Contact: Principal Investigator (Jeanne Palmer, MD)

  • Mayo Clinic Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015
    Contact: Principal Investigator (James Foran, MD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Atish Choudhury, MD) · 877-442-3324
    Contact: Study coordinator (Jia Luo, MD) · 877-442-3324
    Contact: Principal Investigator (Atish Choudhury, MD)

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015
    Contact: Principal Investigator (Mrinal Patnaik, MD)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Rabia Khan) · RKhan@MDAnderson.org · 713-563-4667
    Contact: Principal Investigator (Sarina A Piha-Paul, MD)

  • University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Harini Ramachandran) · phase1clinicaltrial@seattlecca.org
    Contact: Principal Investigator (Michael Schweizer, MD)
Study leads

  • Judy Chiao, MD

    Study Director

    Epigenetix, Inc.

View source on ClinicalTrials.gov(opens in a new tab)